View Older Stories
-
S&P 500 buybacks up 3.2% in Q4 2019; Full Year 2019 down 9.6% from record 2018, as companies brace for a more volatile 2020
-
Pre-Open Stock Movers 02/18: (LM) (BEN) (AAP) Higher; (FLR) (CAG) (CVU) Lower (more...)
-
Biogen (BIIB) PT Raised to $365 at Citi
-
Sarepta shares surge after surprise approval of Duchenne Muscular Dystrophy drug
-
S&P 500 Q2 Stock Buybacks Fall 20.1% Sequentially, 13.7% YoY
-
S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels
-
Citi Assumes Biogen (BIIB) at Neutral
-
UPDATE: Citi Downgrades Biogen (BIIB) to Neutral
-
Biogen (BIIB) fair value is $241/share without AD - Citi
-
Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal
-
Biogen (BIIB) PT Lowered to $470 at Citi
-
S&P 500 Q2 2018 Buybacks Increase 58.7% Year-Over-Year to Record $190.6 Billion
-
Biogen (BIIB) PT Raised to $483 at Citi
-
Citi Upgrades Biogen (BIIB) to Buy
-
Biogen (BIIB) PT Lowered to $290 at Citi
-
Pre-Open Movers 04/24: (EVLV) (SANM) (WFT) Higher; (EPZM) (WAT) (MMM) Lower (more...)
-
S&P keeps New Year's rally alive, Dow eases
-
UPDATE: Citi Downgrades Biogen (BIIB) to Neutral
-
Citi Reiterates Buy Rating on Biogen (BIIB); 'SMA Survey Suggests 11% Spinraza Uptake Already'
-
Biogen (BIIB) PT Raised to $315 at Citi Following Positive Tecfidera Dosing Patent Ruiling by USPTO
-
Pre-Open Movers 02/07: (PRCP) (AVXL) (ATHX) Higher; (FXCM) (KTOV) (KORS) Lower (more...)
-
Citi Upgrades Biogen (BIIB) to Buy
-
Complete Donald Trump Stock Impact Guide
-
Notable Analyst Rating Changes 11/7: (PAH) (BIIB) (CMI) Upgraded; (GPRO) (PNR) (BMRN) Downgraded
-
UPDATE: Biogen's (BIIB) Conference Cancellation Said Due to Scheduling Conflict
-
Biogen (BIIB) on Watch Amid Chatter
-
Pre-Open Stock Movers 08/01: (FLXT) (IONS) (PN) Higher; (VHC) (AMDA) (KERX) Lower (more...)
-
Notable Analyst Rating Changes 6/29: (DYN) (CNC) (DAR) Upgraded; (HAR) (ESPR) (ZION) Downgraded
-
Notable 52-Week Highs and Lows 6/22: (NFX) (EXEL) (CSAL) High; (ALXN) (BIIB) Low
-
Citi Downgrades Biogen (BIIB) to Neutral
-
Citi Starts Biogen (BIIB) at Buy
-
Halvorsen's Viking Global Entered Biogen (BIIB), McDonald's (MCD), Sold Amazon (AMZN), Citi (C) in Q4 - 13F
-
Viking Global Investors's 13F Shows New Stakes in Aflac (AFL), Calpine (CPN), Southwestern Energy (SWN), Liquidates Hilton (HLT) ...
-
Pre-Open Stock Movers 01/27: (CAPN) (FATE) (HA) (BIIB) Higher; (TUP) (X) (BA) (AAPL) Lower (more...)
-
Halvorsen's Viking Global Shows New Stakes in NetFlix (NFLX), 58.com (WUBA), Boston Scientific (BSX), Teva (TEVA) (more...)
-
Notable Analyst Rating Changes 9/1: (SGMS) (BLOX) (VMW) Upgraded; (PTEN) (VRTS) (ENDP) Downgraded
-
Halvorsen's Viking Global Shows New Stakes in Aetna (AET), Amazon (AMZN), Fox (FOXA); Exits Lilly (LLY), Micron (MU), (more...)
-
Unusual 11 Mid-Day Movers 7/24: (SFG) (GLRI) (CALA) Higher; (SNSS) (TRUE) (SPNC) Lower
-
Biogen (BIIB) PT Lifted to $512 at Citi; Questions Remain on Dose/Saftey
-
Notable Mergers and Acquisitions 1/12: (SHPG)/(NPSP) (ABC)/(MWIV) (BIIB) (FMI)/(RHHBY)
-
Heebner's Capital Growth Cuts Micron (MU), Ford (F), Adds BofA (BAC) in Q3
-
Puma Biotechnology (PBYI) Adds to Gains as M&A Speculation Heats Up
-
Semi-Annual Changes to the NASDAQ OMX CRD Global Sustainability Index
-
Viking Global Lifts Facebook (FB), Enters Citi (C), Mondelez (MDLZ) and Nokia (NOK) (more...)
-
Biogen (BIIB) Price Target Lifted to $338 at Citi on Tecfidera and Strong Pipeline
-
Biogen (BIIB) Target Raised to $320 at Citi
-
Pre-Open Stock Movers 9/9: (MOLX) (UNIS) (ISIS) Higher; (BIOD) (HSOL) (SCTY) Lower (more...)
-
Streetinsider.com Pre-Open Movers 07/01: (ONXX) (ACUR) (NOK) Higher; (EZPW) (BBRY) (VLO) Lower (more...)
-
Citi Upgrades Biogen (BIIB) to Buy
-
Notable Analyst Rating Changes 06/12: (HMA) (AMAT) (RVBD) Upgraded; (BIIB) (LM) (USB) Downgraded

